AT LAST: Anti-Thrombotic LymphAtic Stent Therapy
3DT Holdings will pioneer the first-ever minimally invasive device designed specifically for the lymphatic system, which will treat obstructions within the thoracic duct (main lymphatic vessel). The team will also develop a unique device-drug combination: a stent that resists clots, paired with a targeted first-in-class oral medication that works only in the lymphatics.